Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists

J Assoc Physicians India. 2000 Mar;48(3):329-34.

Abstract

Numerous investigators have shown that the glycoprotein IIb/IIIa integrin mediates the final common pathway in platelet aggregation which has led to development of GP IIb/IIIa receptor antagonists. This article reviews the current status of GP IIb/IIIa receptor blockade in the management of coronary artery disease, examining the results of pivotal clinical trials.

Publication types

  • Review

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Coronary Disease / drug therapy*
  • Humans
  • Immunoglobulin Fab Fragments / adverse effects
  • Immunoglobulin Fab Fragments / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Thrombolytic Therapy

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Abciximab